Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies

Summary

Sleuth forecasts an increase in Western licensing deals for Chinese radioligand therapies starting in 2027, noting that deals for such assets have been rare and the pool of potential Western buyers remains limited.